Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2468–2477. doi: 10.1128/aac.40.11.2468

Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.

M Alexov 1, P D Lister 1, C C Sanders 1
PMCID: PMC163559  PMID: 8913448

Abstract

An in vitro pharmacokinetic model (IVPM) and a mouse model of lethal bacteremia were used to compare the pharmacodynamics of ampicillin-sulbactam when the two components were dosed simultaneously and in sequence against TEM-1-producing Escherichia coli. The challenge isolates included three strains of E. coli producing various levels of beta-lactamase. Human pharmacokinetics of ampicillin-sulbactam (1.5- and 3.0-g intravenous doses) were simulated in each model, and pharmacodynamic interactions were evaluated over one 6-h dosing interval. Against all three strains, the sequential dosing of sulbactam prior to ampicillin did not alter the pharmacodynamics of these combinations from comparison with results obtained with the simultaneous administration of the two components. Similar pharmacodynamics were observed for the two dosing regimens regardless of the ampicillin-sulbactam dose used or whether the bacteria were treated in an immunocompetent mouse or in the absence of immune defenses in the IVPM. When antibacterial activity was lost and regrowth of the inoculum was observed, viable bacterial counts increased in both the simultaneous and sequential regimens at a point when sulbactam levels fell below a critical concentration. These data suggest that the efficacy of ampicillin-sulbactam is not dependent upon the maintenance of a constant 2:1 ratio for the two components. Rather, the efficacy of ampicillin-sulbactam appears to be dependent upon the maintenance of one or both components above a critical concentration. Furthermore, the pharmacokinetics of sulbactam, specifically, how long sulbactam levels remain above a minimum critical concentration, appears to dictate how long antibacterial activity is maintained with the combination.

Full Text

The Full Text of this article is available as a PDF (251.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaser J., Stone B. B., Zinner S. H. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):131–137. doi: 10.1093/jac/15.suppl_a.131. [DOI] [PubMed] [Google Scholar]
  2. Bradford P. A., Sanders C. C. Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam. Antimicrob Agents Chemother. 1993 Feb;37(2):251–259. doi: 10.1128/aac.37.2.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brenner D. G., Knowles J. R. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 alpha- and 6 beta-monodeuterio and of 6,6-dideuterio derivatives with RTEM beta-lactamase from Escherichia coli. Biochemistry. 1981 Jun 23;20(13):3680–3687. doi: 10.1021/bi00516a003. [DOI] [PubMed] [Google Scholar]
  4. Campoli-Richards D. M., Brogden R. N. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987 Jun;33(6):577–609. doi: 10.2165/00003495-198733060-00003. [DOI] [PubMed] [Google Scholar]
  5. Cavalieri S. J., Sanders C. C., New C. Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes. Antimicrob Agents Chemother. 1991 Jul;35(7):1343–1347. doi: 10.1128/aac.35.7.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis. 1986 Nov-Dec;8 (Suppl 5):S503–S511. doi: 10.1093/clinids/8.supplement_5.503. [DOI] [PubMed] [Google Scholar]
  7. Friedman H., Warren G. H. Increased phagocytosis of Escherichia coli pretreated with subinhibitory concentrations of cyclacillin or ampicillin. Proc Soc Exp Biol Med. 1982 Feb;169(2):301–305. doi: 10.3181/00379727-169-41347. [DOI] [PubMed] [Google Scholar]
  8. Jarvis W. R., Martone W. J. Predominant pathogens in hospital infections. J Antimicrob Chemother. 1992 Apr;29 (Suppl A):19–24. doi: 10.1093/jac/29.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  9. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  10. Lister P. D., Sanders C. C. Comparison of ampicillin-sulbactam regimens simulating 1.5- and 3.0-gram doses to humans in treatment of Escherichia coli bacteremia in mice. Antimicrob Agents Chemother. 1995 Apr;39(4):930–936. doi: 10.1128/aac.39.4.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lorian V., Atkinson B. A. Effect of serum and blood on Enterobacteriaceae grown in the presence of subminimal inhibitory concentrations of ampicillin and mecillinam. Rev Infect Dis. 1979 Sep-Oct;1(5):797–806. doi: 10.1093/clinids/1.5.797. [DOI] [PubMed] [Google Scholar]
  12. Sanders C. C., Sanders W. E., Jr Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother. 1979 Jun;15(6):792–797. doi: 10.1128/aac.15.6.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sanders C. C., Sanders W. E., Jr, Moland E. S. Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother. 1986 Dec;30(6):951–952. doi: 10.1128/aac.30.6.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sanders C. C., Sanders W. E., Jr beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis. 1992 Nov;15(5):824–839. doi: 10.1093/clind/15.5.824. [DOI] [PubMed] [Google Scholar]
  15. Schaberg D. R., Culver D. H., Gaynes R. P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991 Sep 16;91(3B):72S–75S. doi: 10.1016/0002-9343(91)90346-y. [DOI] [PubMed] [Google Scholar]
  16. Strayer A. H., Gilbert D. H., Pivarnik P., Medeiros A. A., Zinner S. H., Dudley M. N. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct;38(10):2351–2356. doi: 10.1128/aac.38.10.2351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Watanabe Y., Tawara S., Mine Y., Kikuchi H., Goto S., Kuwahara S. Synergism of cephalosporins at subinhibitory concentrations and polymorphonuclear leukocytes on phagocytic killing of Escherichia coli and its mode of action. J Antibiot (Tokyo) 1986 Feb;39(2):294–303. doi: 10.7164/antibiotics.39.294. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES